FNCHQ (Finch Therapeutics Group) Current Accrued Expense: $2.32 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNCHQ Finch Therapeutics Group Inc FNCHQ
12 GF Score
Price $10.20
View Full Analysis

What is Finch Therapeutics Group Current Accrued Expense?

Finch Therapeutics Group FNCHQ 12 Current Accrued Expense is $2.32 Mil as of Jun. 2024. GuruFocus rates FNCHQ with a GF Score™ of 12/100.

Finch Therapeutics Group's Current Accrued Expense for the quarter that ended in Jun. 2024 was $2.32 Mil.

Finch Therapeutics Group's quarterly Current Accrued Expense declined from Dec. 2023 ($1.68 Mil) to Mar. 2024 ($1.43 Mil) but then increased from Mar. 2024 ($1.43 Mil) to Jun. 2024 ($2.32 Mil).

Finch Therapeutics Group's annual Current Accrued Expense increased from Dec. 2021 ($5.52 Mil) to Dec. 2022 ($8.61 Mil) but then declined from Dec. 2022 ($8.61 Mil) to Dec. 2023 ($1.68 Mil).

Finch Therapeutics Group Current Accrued Expense Related Terms

Finch Therapeutics Group Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Finch Therapeutics Group's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Finch Therapeutics Group Current Accrued Expense Chart

Finch Therapeutics Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
1.77 1.70 5.52 8.61 1.68

Finch Therapeutics Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.01 2.54 1.68 1.43 2.32
FNCHQ
12GF Score
Finch Therapeutics Group Inc FNCHQ
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Finch Therapeutics Group Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $2.32 Mil mean?
Finch Therapeutics Group (FNCHQ) has a Current Accrued Expense of $2.32 Mil as of Jun. 2024. Current Accrued Expense records the total amount of accrued expenses. View historical data on Finch Therapeutics Group and its competitors.
Is Finch Therapeutics Group's Current Accrued Expense too high?
Finch Therapeutics Group's current Current Accrued Expense is $2.32 Mil. Overall, Finch Therapeutics Group has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Finch Therapeutics Group's Current Accrued Expense compare to CRIS and LSB?
Finch Therapeutics Group's Current Accrued Expense of $2.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Finch Therapeutics Group and its competitors. Finch Therapeutics Group's current Current Accrued Expense is $2.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Finch Therapeutics Group stock overvalued right now?
Finch Therapeutics Group (FNCHQ) has a current Current Accrued Expense of $2.32 Mil. The current Current Accrued Expense is $2.32 Mil. Finch Therapeutics Group's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Finch Therapeutics Group (FNCHQ), the current Current Accrued Expense is $2.32 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Finch Therapeutics Group Business Description

Address 75 State Street, Suite 100, Boston, MA, USA, 02109
Finch Therapeutics Group Inc is a microbiome technology company with a portfolio of intellectual property and microbiome assets. Finch has a robust intellectual property estate reflecting the company's pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. The company's assets include CP101, an investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI).
12GF Score

Get the complete analysis for FNCHQ

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.20
Price